3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Gallbladder Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
Doxorubicin
62
Ifosfamide
39
Gemcitabine
29
Radiotherapy
27
Filgrastim
27
Cyclophosphamide
26
Docetaxel
19
Vincristine
18
pembrolizumab
17
Etoposide
17
pazopanib
16
Cisplatin
16
Nivolumab
15
Trabectedin
14
apatinib
13
Magnetic Resonance Spectroscopy
13
Carboplatin
12
Irinotecan
11
Bevacizumab
11
anlotinib
10
Temozolomide
10
Surgical Procedures, Operative
10
Sirolimus
10
camrelizumab
9
Sorafenib
9
Paclitaxel
9
Ipilimumab
9
Injections
9
Dactinomycin
9
Topotecan
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Sarcoma
×
bintrafusp alfa protein, human
×
Clear all
NCT04874311
2025-08-13
TRUST
Institut Bergonié
Phase 2
Recruiting
80 enrolled